• Kura Oncology released an ASCO 2026 investor presentation detailing a clinical update for darlifarnib, a next-generation farnesyl transferase inhibitor.
• FIT-001 Phase 1 data showed tumor shrinkage in 77% (20/26) of response-evaluable KRAS G12C patients on darlifarnib plus adagrasib.
• KRAS inhibitor-naïve subgroup recorded tumor shrinkage in 94% (15/16); shrinkage also observed in KRAS inhibitor-pretreated patients.
• Safety profile featured high GI events; grade 3 or higher TEAEs were 53% at 3 mg, 80% at 5 mg across 30 treated patients.
• Cash and investments were $580.8 million as of 3/31/26; the presentation also cited $180 million in anticipated payments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.